但值得一提的是， 2022年10月，和铂医药将巴托利单抗的大中华区权益授权给石药集团，后者支付1.5亿元预付款，8.61亿元里程碑金额，以及一定比例的销售分成，协议总金额超过10亿元，创下国内FcRn赛道纪录。

这篇综述系统阐述了新生儿Fc受体（FcRn）在IgG抗体稳态调控中的核心作用，及其作为创新治疗靶点在自身免疫性疾病中的应用价值。文章详细解析了FcRn与IgG的pH依赖性结合机制（1:2化学计量比），综述了efgartigimod（ARGX-113）、rozanolixizumab（UCB7665）等5种临床阶段 ...

Immunovant, Inc. had positive results for batoclimab in trials for Myasthenia Gravis & CIDP; Thyroid Eye Disease data ...

新生儿 Fc 受体（FcRn）抑制剂艾加莫德（Efgartigimod ... 通过重症肌无力日常生活活动能力量表（MG-ADL）、定量重症肌无力量表（QMG）、重症肌无力复合量表（MGC）和重症肌无力生活质量 15 项修订版量表（MGQoL15r）评估治疗效果。结果显示，平均随访时间为 21±5 ...

Switching to IMVT-1402 extends the head starts Immunovant has already ceded to its rivals. Argenx won FDA approval for ...

Investing.com — 周四，Stifel分析师将Immunovant（NASDAQ:IMVT）股票的目标价从此前的58.00美元上调至61.00美元，同时重申对该股的买入评级。这与广泛的分析师共识一致， InvestingPro ...

Myasthenia gravis (MG) results from autoimmune antibodies against the post-synaptic neuromuscular junction with three major ...

Despite meaningful improvement for patients with MG and CIDP to date with the anti-FcRn class, there continues to be significant unmet need. IMVT-1402 is a potentially best-in-class anti-FcRn that may ...

Immunovant (IMVT) reported topline results from its Phase 3 study of batoclimab in MG and initial results from Period 1 of its Phase 2b study ...

Immunovant (IMVT) reported best absolute improvements with IMVT-1402 in myasthenia gravis and chronic inflammatory demyelinating ...

Roivant Sciences Ltd. CEO Matt Cline said the firm’s unit Immunovant Inc. with FcRn blocker batoclimab has established “frankly a new bar” in myasthenia gravis (MG) as the New York-based firm reported ...